Glycated hemoglobin levels correlate strongly with continuous glucose monitoring-measured average blood glucose and hyperglycemia, but poorly with hypoglycemia, say researchers.
People in the general population typically believe that they have a low risk for type 2 diabetes, regardless of what their actual risk is, show the results of a German national survey focusing on diabetes-related knowledge.
The recent postmarketing data on Fournier gangrene in people taking sodium-glucose cotransporter 2 inhibitors has increased concerns about this very rare but potentially fatal side effect. medwireNews talks to primary care diabetes specialist Kevin Fernando about how the findings affect risk–benefit considerations.
Detailed analysis of renal outcomes in the DECLARE-TIMI 58 trial confirms that treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin is renoprotective in patients with type 2 diabetes and preserved kidney function.
Researchers have used exome-wide sequencing to identify several rare variants within four genes that are significantly associated with type 2 diabetes.
Diabetologist Sanjay Kalra puts the CAROLINA trial into historical context and considers the present-day implications for the use of DPP-4 inhibitors and sulfonylureas.
WATCH | Nephrologist Katherine Tuttle and Primary Care Physician Jay Shubrook discuss discuss referrals to nephrology for patients with comorbid diabetes and kidney disease (8:38).
Fournier gangrene remains very rare, but is more common in people using SGLT2 inhibitors compared with other diabetes medications and has severe consequences, shows research.
What does the proliferation of diabetes self-management and monitoring technologies in pediatric care mean for the future of adult services? Katharine Barnard looks at the situation in England.
The Ellipse investigators report improved glycemic control at the price of early and mostly mild gastrointestinal events in children and adolescents with type 2 diabetes.
Escalating obesity prevalence and severity has led to type 2 diabetes being diagnosed in ever-younger people, including children. medwireNews rounds up the accumulating evidence suggesting a particularly severe diabetes course in these young people.
Findings from the CREDENCE trial indicate that the SGLT2 inhibitor canagliflozin reduces the risk for renal failure and cardiovascular disease among individuals with type 2 diabetes and albuminuric chronic kidney disease.
Join John Wilding, Kamlesh Khunti, and Julie Lovshin on Wednesday 8 May at 19:00-20:00 (BST) for a live webinar discussion with an expert faculty on the continuing evolution of glucagon-like peptide-1 receptor agonists (GLP-1RAs). Find out more and register here.
Oral semaglutide offers greater efficacy for glucose control and weight loss when compared with sitagliptin for people with type 2 diabetes, although with more adverse events at the highest dose, show the PIONEER 3 findings.
How will the findings of the REWIND trial and the DECLARE-TIMI 58 renal outcomes analysis affect treatment decisions for high-risk diabetes patients without overt cardiovascular disease? medwireNews asks Kamlesh Khunti.
Diabetologist Sanjay Kalra puts the CAROLINA trial into historical context and considers the present-day implications for the use of DPP-4 inhibitors and sulfonylureas.
These slide sets summarize the results of randomized controlled trials investigating the use of flash glucose-sensing technology in patients with diabetes.
Funded by an educational grant from Abbott Diabetes Care
An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.
A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.
Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.
Themed collections
Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.
Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.
